GCKR抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Mouse liver tissue, Primary antibody: P04902(GCKR Antibody) at dilution 1/750, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P04902(GCKR Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P04902(GCKR Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

GCKR (glucokinase regulatory protein) is a key metabolic regulator primarily expressed in the liver and pancreatic β-cells. It interacts with glucokinase (GCK), a rate-limiting enzyme in glucose metabolism, to modulate its activity in response to nutritional states. By sequestering GCK in the nucleus during fasting, GCKR reduces hepatic glucose phosphorylation, while postprandial fructose metabolites release GCK to enhance glycolysis and glycogen synthesis. Dysregulation of GCKR is linked to metabolic disorders, including type 2 diabetes (T2D), hypertriglyceridemia, and non-alcoholic fatty liver disease (NAFLD). Genome-wide studies highlight GCKR variants (e.g., rs780094. rs1260326) as susceptibility loci for these conditions, likely through altered lipid and glucose homeostasis.

Antibodies targeting GCKR are vital tools in studying its expression, localization, and interaction networks. They enable detection of GCKR in tissues, assessment of post-translational modifications, and exploration of molecular mechanisms underlying metabolic diseases. Additionally, autoantibodies against GCKR have been investigated in rare autoimmune contexts, though their clinical significance remains unclear. Research leveraging GCKR antibodies continues to unravel its role in metabolic pathways, offering insights into therapeutic strategies for disorders tied to insulin resistance and dyslipidemia.